SIRPA and glioblastoma: Inhibiting the CD47/SIRPα anti-phagocytic and pro-M2 axis in GBM has shown promising results by shifting macrophages towards the antitumorigenic M1 phenotype, reducing tumor burden by enhancing macrophage-mediated phagocytosis, and improving survival in xenograft mouse models (Zhang et al., 2016; Gholamin et al., 2017).